Distribution (GDP)9 min read

Wholesale distribution authorisation (WDA) in Belgium: how to prepare an application or a change

What a Belgian pharmaceutical wholesale licence permits, what the FAMHP expects in the application, who can be the Responsible Person and what changes once the authorisation is granted.

MEDCORRegulatory and quality consultancy led by Hendrik Staels

Published Also available inNederlandsFrançais

ShareLinkedInWhatsAppEmail

To buy, hold, supply or export medicinal products as a wholesaler in Belgium, a company needs a wholesale distribution authorisation (WDA) from the FAMHP. The application is made on the agency's form, names a qualified Responsible Person and is followed by an inspection against Good Distribution Practice (GDP). The legal period for a decision is 90 days from a valid application. Most of the work sits before submission: deciding the scope, preparing the site and building a quality system that matches what you will do.

What the authorisation permits, and when you need it

The legal basis is Article 12ter of the Medicines Act of 25 March 1964 and Articles 90 to 99 of the Royal Decree of 14 December 2006 (opens in a new tab) (Dutch). People call the same document a wholesale distribution authorisation, a WDA, a pharmaceutical wholesale licence or, in Belgium, a groothandelsvergunning or autorisation de distribution en gros.

The FAMHP describes distribution as every activity around the purchase, receipt, storage, delivery, sale and export of medicines, together with stock management, transport, documentation, traceability, complaint handling and recalls. In practice:

  • You need it if you procure, hold, supply or export medicines for human use as a business, including when storage is outsourced and you never see the goods.
  • A manufacturer or importer may distribute the medicines covered by its manufacturing authorisation, but must then meet the same wholesale obligations (Art. 95 §1).
  • Transport alone does not require an authorisation, according to the FAMHP's GDP questions and answers (opens in a new tab) (Dutch). The wholesaler who orders the transport stays responsible for it. Temporary storage that goes beyond what transport needs can require an authorisation.
  • Brokers do not buy or hold medicines. They register with the FAMHP instead (Art. 101bis).
  • Medical devices are outside the GDP guidelines for medicines.

Three documents are often confused. The authorisation allows the company to carry out the listed activities at the listed site. A GDP certificate records the outcome of an inspection and is published in the EudraGMDP database (opens in a new tab). A marketing authorisation belongs to a product, not to a distributor.

The authority, and why scope matters

The Federal Agency for Medicines and Health Products (FAMHP, FAGG in Dutch, AFMPS in French) grants the authorisation on behalf of the Minister. Its authorisations page (opens in a new tab) carries the current form and instructions.

The authorisation lists the activities you applied for, and your activities must then stay within it. Decide these points before you fill in the form:

  • Activities. Procuring, holding, supplying, exporting, or a combination.
  • Site. The premises where medicines are stored or from which the activity is managed, including any outsourced warehouse.
  • Products. The application must specify the medicines you intend to distribute (Art. 90). Cold-chain products change the premises and transport requirements. Narcotics and psychotropic substances need a separate activity authorisation.
  • Customers. Supplying pharmacies, other wholesalers or customers outside the EU each brings its own checks. Wholesale to third countries follows Art. 99bis.
  • Public service obligations. A full-line wholesaler (groothandelaar-verdeler, grossiste-répartiteur) takes on stock and delivery duties under Art. 100 and 101.

What an application involves

The FAMHP sets out the route in a one-page note, how to apply for an authorisation to distribute medicines (opens in a new tab) (Dutch), and on its authorisations page. In outline:

  1. Check your organisation data. The FAMHP asks applicants to make sure the company is correctly registered in the EMA's Organisation Management Service (OMS) (opens in a new tab) first.
  2. Complete the application form. One FAMHP form covers a new application, a change and a withdrawal. It must be fully completed and signed by a person entitled to represent the company under its articles of association.
  3. Send it by e-mail with the annexes. The form and the annexes it lists go to eudragmdp@fagg.be, each document as a separate, clearly named attachment, with the subject line the FAMHP prescribes on its page.
  4. Admissibility. When the FAMHP declares the application admissible, your contact person receives a confirmation and the details of the inspector who will assess GDP compliance.
  5. Inspection. The inspector checks the information supplied and conformity with GDP (Art. 97).
  6. Decision. The FAMHP decides on the basis of the inspection conclusions and any corrective actions.

The decision is due within 90 days of a valid application (Art. 91). The period is suspended while the agency waits for additional information it has asked for (Art. 93), which the FAMHP calls a clock-stop. You may start distributing only after the authorisation is granted.

On cost, the FAMHP states that issuing the authorisation is covered by the annual contribution every authorisation holder owes, that the amount is indexed each year and that an additional inspection is charged separately. We do not quote amounts here because they change; check the agency's contributions page (opens in a new tab) (Dutch) for the current year.

What to prepare

Art. 90 asks for three things: suitable premises, installations and equipment; qualified staff, including a Responsible Person; and a commitment to meet the holder's obligations in Art. 94. Translated into a working file:

AreaWhat to have ready
CompanyLegal entity details matching the OMS registration, the person entitled to sign, a contact reachable at all times for urgent cases (Art. 94, 11°)
Activities and productsThe activities applied for, the medicines or product categories, storage conditions, intended suppliers and customer types
Premises and equipmentSite plan, segregated areas, temperature monitoring and mapping where needed, security, calibration and maintenance records
Quality systemQuality manual, SOPs, deviation and CAPA handling, change control, complaints, returns, falsified medicines, the emergency plan for recalls (Art. 94, 6°), self-inspection programme, training programme
RecordsA system that captures every transaction with date, product, quantity, supplier or customer and batch number where required, kept for five years (Art. 94, 7° and 8°)
Outsourced activitiesWritten contracts with warehouse and transport partners, and an audit of each before work starts
Responsible PersonDiploma, contract and job description with decision authority, presence schedule per distribution point, record of delegated duties

The Responsible Person: eligibility and role

Belgian law is more specific than the EU guideline, which only calls a pharmacy degree desirable. Under Art. 95 §2 the Responsible Person must hold the legal diploma of pharmacist, physician, veterinarian, chemist, biologist, biomedical scientist or bio-engineer, or the corresponding master’s degree. The FAMHP's questions and answers add that experience cannot replace the diploma, that a foreign diploma must be shown to be equivalent, that nationality and place of residence do not matter, and that only one person can be appointed as Responsible Person per authorisation.

The holder must make sure the Responsible Person is present when distribution activities take place. A part-time arrangement needs a precise schedule, stated per distribution point when there are several (Art. 94, 10°). Section 2.2 of the EU GDP Guidelines (opens in a new tab) describes the role itself: the Responsible Person acts personally, stays contactable, may delegate duties but not responsibility, and needs a written job description with the authority to take decisions.

If nobody in your company holds a listed diploma, or your Responsible Person is leaving, an external appointment can be the answer. Our page on the named GDP Responsible Person service explains how we assess and take on that role.

Inspection and follow-up

For a first authorisation the inspection takes place before the decision. Expect the inspector to compare the site and the quality system with what the form says, to ask how the Responsible Person will exercise the role in practice and to test whether staff know the procedures. Findings lead to corrective actions, and the FAMHP takes those into account when it decides.

If the agency intends to refuse, the applicant has 15 days from receiving the draft decision to ask that the file be submitted for an opinion before the decision becomes final (Art. 98). After the authorisation is granted, inspections continue periodically. Our GDP inspection checklist for Belgium covers the evidence to have ready.

Changing an existing authorisation

The holder must inform the FAMHP at least 15 days before any change to the information supplied with the application (Art. 94, 5°). The same application form is used, marked as a change.

  • Premises, equipment or obligations. The FAMHP decides on such a change within 30 days of a valid request, extendable to 90 days in exceptional cases with reasons given (Art. 92).
  • Responsible Person. A planned change is notified in advance like any other. An unexpected replacement is notified without delay.
  • New activities or product categories. Treat these as a scope change and check whether the site, the procedures and the training still fit before you apply.

Our advice: plan a change of Responsible Person with an overlap and a written handover of open deviations, CAPA, supplier and customer approvals and inspection commitments.

After the authorisation: ongoing obligations

Art. 94 lists what a holder must keep doing. Among other things, the holder must:

  • obtain medicines only from authorised suppliers and supply only authorised customers, with checks on both;
  • follow GDP as laid down in Annex V of the Royal Decree and keep a quality system that sets out responsibilities, procedures and risk management;
  • keep transaction records for five years and provide overviews when the FAMHP asks;
  • maintain an emergency plan so that a recall can be carried out;
  • inform the FAMHP immediately about medicines identified or suspected as falsified;
  • give FAMHP inspectors access to the premises at any time.

The FAMHP also expects loss or theft of medicines to be reported as soon as possible, and an annual contribution is due for as long as the authorisation is held. Day to day, the Responsible Person oversees supplier and customer approval, training, deviations, returns, recalls and self-inspections.

Common gaps that slow readiness

These are observations from our own projects, not an official list.

  • Company data in OMS that does not match the application.
  • A form that describes more, or fewer, activities than the business will carry out.
  • Generic procedures that do not reflect the real flow of goods and documents.
  • Contracts with logistics partners signed, but no audit performed before the start.
  • No temperature mapping, or mapping that does not cover seasonal variation where it is needed.
  • A Responsible Person named without a job description, a presence schedule or a record of delegated duties.
  • A recall plan that has never been tested.
  • Supplier and customer approvals without evidence of the authorisation check.

Preparation checklist

  • Scope decided: activities, site, products, customers.
  • OMS registration checked.
  • Responsible Person identified, diploma verified, contract and job description signed.
  • Presence schedule written for each distribution point.
  • Premises ready, monitored and, where needed, mapped.
  • Quality system written, approved and trained.
  • Outsourced partners contracted and audited.
  • Suppliers and customers qualified.
  • Recall plan and permanent contact number in place.
  • Record system able to produce transaction data for five years.
  • Application form completed, signed and sent with annexes.
  • Team briefed for the inspection.

Where MEDCOR can help

We prepare applications and changes, build GDP quality systems, qualify logistics partners and prepare teams for inspection. Hendrik Staels can also act as the named Responsible Person where the scope and schedule make that workable. If your team needs training alongside, MEDCOR Academy is preparing an Advanced GDP course for Responsible Persons and QA professionals.

To talk through an application, a change or an appointment, see our Responsible Person service or send us the outline of your project.

ShareLinkedInWhatsAppEmail
MEDCORRegulatory and quality consultancy led by Hendrik StaelsMEDCOR is the independent regulatory affairs and quality assurance consultancy of Hendrik Staels, industrial pharmacist. This guide was prepared by MEDCOR from the official sources cited in the text.
About MEDCOR

Information as at 18 November 2026. Rules, forms, fees and deadlines can change, so check the cited sources before you act. This guide is general information, not legal advice.

Applying for a WDA or changing one?

Tell us your scope and timing. We will say what is needed and where we can help.

Discuss your authorisation